The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
1 Year | 5 Year | 5 Year Annualized | Since IPO | |
---|---|---|---|---|
ATHA | -25.71% | -97.97% | -54.12% | -98% |
S&P | +14.5% | +93.32% | +14.09% | +102% |
Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. Its product pipeline includes ATH-1017, ATH-1019/20, and ATH-1018. The company was founded by Leen Kawas, John Wright, Lewis Rumpler, and Joseph Harding in March 2011 and is headquartered in Bothell, WA.
Q2 2025 | YOY Change | |
---|---|---|
Revenue | $0.00M | 0.0% |
Gross Profit | -$0.20M | 17.4% |
Market Cap | $11.91M | -88.3% |
Market Cap / Employee | $0.46M | 0.0% |
Employees | 26 | -61.2% |
Net Income | -$6.97M | 74.1% |
EBITDA | -$7.09M | 74.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
Q2 2025 | YOY Change | |
---|---|---|
Net Cash | $19.89M | -75.8% |
Accounts Receivable | $0.00M | 0.0% |
Inventory | 0 | 0.0% |
Q2 2025 | YOY Change | |
---|---|---|
Long Term Debt | $0.58M | -43.1% |
Short Term Debt | $0.44M | 12.3% |
Q2 2025 | YOY Change | |
---|---|---|
Return On Assets | -81.54% | -10.5% |
Return On Invested Capital | -73.32% | -134.7% |
Q2 2025 | YOY Change | |
---|---|---|
Free Cash Flow | -$7.00M | 68.7% |
Operating Free Cash Flow | -$7.00M | 68.7% |
Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
---|---|---|---|---|---|
Price to Book | 0.30 | 0.51 | 0.30 | 0.37 | -60.86% |
Price to Tangible Book Value | 2.06 | 3.94 | 2.48 | 3.16 | -66.81% |
Enterprise Value to EBITDA | 2.33 | 1.78 | 2.63 | 2.40 | -2342.02% |
Return on Equity | -102.9% | -110.8% | -110.7% | -103.8% | 22.75% |
Total Debt | $1.31M | $1.22M | $1.12M | $1.02M | -27.72% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.